Nano-Based Co-Delivery System for Treatment of Rheumatoid Arthritis.
Shixin ZhangMiaomiao ZhangXiangyu LiGe LiBo YangXinyue LuYang GaoFengying SunPublished in: Molecules (Basel, Switzerland) (2022)
A systemic autoimmune condition known as rheumatoid arthritis (RA) has a significant impact on patients' quality of life. Given the complexity of RA's biology, no single treatment can totally block the disease's progression. The combined use of co-delivery regimens integrating various diverse mechanisms has been widely acknowledged as a way to make up for the drawbacks of single therapy. These days, co-delivery systems have been frequently utilized for co-treatment, getting over drug limitations, imaging of inflammatory areas, and inducing reactions. Various small molecules, nucleic acid drugs, and enzyme-like agents intended for co-delivery are frequently capable of producing the ability to require positive outcomes. In addition, the excellent response effect of phototherapeutic agents has led to their frequent use for delivery together with chemotherapeutics. In this review, we discuss different types of nano-based co-delivery systems and their advantages, limitations, and future directions. In addition, we review the prospects and predicted challenges for the combining of phototherapeutic agents with conventional drugs, hoping to provide some theoretical support for future in-depth studies of nano-based co-delivery systems and phototherapeutic agents.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- nucleic acid
- chronic kidney disease
- current status
- stem cells
- oxidative stress
- type diabetes
- interstitial lung disease
- combination therapy
- ejection fraction
- mesenchymal stem cells
- photodynamic therapy
- mass spectrometry
- adipose tissue
- skeletal muscle
- systemic sclerosis
- patient reported outcomes
- replacement therapy
- patient reported